Follow our progress.

Milestones in our journey to reinvent genetic testing.

Back to full list

Press Releases

Invitae announces multiple scientific presentations and posters to be presented at the American Society of Human Genetics 2016 Annual Meeting

Invitae announces multiple scientific presentations and posters to be presented at the American Society of Human Genetics 2016 Annual Meeting

October 19, 2016

14 posters and presentations to focus on advances in genetic testing technology and medical interpretation tools as well as new applications of genetics in health and wellness

This week Invitae Corporation (NYSE: NVTA), a genetic information company, is presenting multiple abstracts at the American Society of Human Genetics (ASHG) 2016 Annual Meeting in Vancouver, covering an array of topics in genetics, including advances in complex variant detection and medical interpretation, as well as survey data exploring the attitudes of healthy ...

Read more


Invitae announces collaboration with Helix to build applications for health and wellness

Invitae announces collaboration with Helix to build applications for health and wellness

October 18, 2016

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced a collaboration with Helix, a personal genomics company, to build novel, clinician-approved genetic testing applications designed to work with Helix’s CLIA-certified DNA sequencing platform to provide screening applications for health and wellness. Individuals who utilize the Helix consumer platform will be able to select health applications from Invitae pending approval by a clinician. Invitae will then provide a full interpretation of the results.

Through this collaboration, Invitae will offer some ...

Read more


Invitae announces final Medicare pricing set at $925 for hereditary breast cancer-related disorders under new billing process

Invitae announces final Medicare pricing set at $925 for hereditary breast cancer-related disorders under new billing process

October 03, 2016

Invitae Corporation (NYSE: NVTA), a genetic information company, announced that the Centers for Medicare and Medicaid Services (CMS) announced final pricing for genetic testing for hereditary breast cancer-related disorders (e.g. hereditary breast cancer, hereditary ovarian cancer, and hereditary endometrial cancer). The tests are billed under the new current procedure terminology (CPT) code 81432, which became effective on January 1, 2016. CMS had previously announced a temporary payment per test of $622.53, and -- after a public comment period -- the ...

Read more


Genetic Counselors Recognized by Patients, Peers for Excellence in Patient Care

Genetic Counselors Recognized by Patients, Peers for Excellence in Patient Care

September 30, 2016

Finalists and winner for Genome magazine’s Code Talker Award announced and honored at the National Society of Genetic Counselors (NSGC) Annual Education Conference

At the National Society of Genetic Counselors (NSGC) Annual Education Conference in Seattle, Allison Goetsch, MS, CGC, genetic counselor at Ann & Robert H. Lurie Children’s Hospital of Chicago was announced as the winner of the inaugural Code Talker Award. The Code Talker Award, sponsored by Invitae Corporation (NYSE: NVTA), was established by Genome magazine to recognize ...

Read more


Invitae presenting research on genetic test panels, increasing access to genetic counseling at the National Society of Genetic Counselors 35th Annual Education Conference

Invitae presenting research on genetic test panels, increasing access to genetic counseling at the National Society of Genetic Counselors 35th Annual Education Conference

September 28, 2016

This week Invitae Corporation (NYSE: NVTA), a genetic information company, is participating in the National Society of Genetic Counselors (NSGC) 35th Annual Education Conference in Seattle, highlighting new research on genetic testing for preventive care and new strategies for providing remote access to genetic counseling services.

NSGC is the largest scientific session for genetic counselors. Invitae’s presenters will discuss:

  • The role of genetic testing in guiding preventive care is an area of keen interest for many patients and their primary ...

Read more


Invitae announces major expansion of its neurology and cardiology test offerings

Invitae announces major expansion of its neurology and cardiology test offerings

August 15, 2016

Introduces new panels for Parkinson’s disease, neuropathies, and neuromuscular diseases

Adds new genes to panels for arrhythmias, cardiomyopathies, aortopathies, and congenital heart disease; introduces a new cardiomyopathy and skeletal muscle disease panel

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it has expanded its neurology and cardiology test offering, adding 11 new panels for heritable diseases. In addition, Invitae has updated 17 existing neurology panels and eight cardiology panels based on new discoveries in genetics research.

With ...

Read more


Invitae announces second quarter 2016 financial results, secures contract with a national payer and expands its network of regional private payers

Invitae announces second quarter 2016 financial results, secures contract with a national payer and expands its network of regional private payers

August 08, 2016

Accelerated development of a 20,000-gene medical exome to be available in Q1:2017

Nearly tripled volume with more than 12,000 test reports delivered

Lowered COGS to approximately $500

Signed first biopharma agreements

Hosting webinar/conference call at 4:45 pm ET / 1:45 pm PT

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced financial and operating results for the second quarter ended June 30, 2016. The company made substantial progress on all four of its key ...

Read more


Invitae to present at the Canaccord Genuity 36th Annual Growth Conference

Invitae to present at the Canaccord Genuity 36th Annual Growth Conference

July 28, 2016

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that members of the company’s management team will present at the Canaccord Genuity 36th Annual Growth Conference on Thursday, August 11, 2016 at approximately 12:30 p.m. Eastern in Boston.

The live, listen-only webcast of the presentation may be accessed by visiting the investors section of the company’s website at ir.invitae.com. A replay of the webcast will be available shortly after the conclusion of the presentation and ...

Read more


Invitae to announce second quarter 2016 financial results and host conference call on August 8, 2016

Invitae to announce second quarter 2016 financial results and host conference call on August 8, 2016

July 25, 2016

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it will report its second quarter 2016 financial results on Monday, August 8, 2016 and will host a conference call that day at 4:45 pm Eastern / 1:45 pm Pacific to discuss its financial results and recent developments.

The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers, and the reservation number for both is 48736029.

The live, listen-only ...

Read more


Invitae introduces new Breast Cancer STAT Panel for patients with breast cancer who need rapid test results to guide surgical decisions

Invitae introduces new Breast Cancer STAT Panel for patients with breast cancer who need rapid test results to guide surgical decisions

July 20, 2016

Test offers rapid turnaround time on seven genes that may influence surgical options and treatment decisions

Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that the company now offers a new Breast Cancer STAT Panel of high-quality genetic testing designed for breast cancer patients whose providers need a fast turnaround time to guide treatment and management.

Invitae’s new Breast Cancer STAT Panel includes seven genes with surgical and therapeutic relevance: BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, and TP53 ...

Read more